Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2006

01.12.2006 | Original Article

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas

verfasst von: Michael J. Ciesielski, Lisa Apfel, Tara A. Barone, Carla A. Castro, Tina C. Weiss, Robert A. Fenstermaker

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Survivin is a member of the inhibitor of apoptosis protein family. Gliomas and many other tumors express survivin at high levels; whereas, normal fully differentiated cells generally do not. Therefore, survivin represents a tumor-specific target for cancer vaccine therapy. It has been shown that it is possible to produce a MHC-I-restricted cellular immunologic response to survivin vaccines. To study differences in immunogenicity between murine and human survivin proteins, we vaccinated C57BL/6 mice with bone marrow dendritic cells (BMDC) transfected with expression vectors containing the murine and human survivin genes. Mice vaccinated with BMDCs expressing a truncated human survivin protein developed cytotoxic T lymphocyte to subcutaneous GL261 glioma cells and exhibited prolonged tumor-free survival compared to mice vaccinated with BMDCs transfected with vector alone (P<0.01). While mice challenged with intracerebral GL261 cells had increased survival, no cures were observed. In contrast, vaccinated mice that fully resisted subcutaneous tumor challenge were rendered resistant to intracerebral GL261 re-challenge. BMDCs transfected with the full-length human survivin molecule were significantly more effective at prolonging survival than BMDCs expressing the full-length murine survivin gene (P=0.0175). Therefore, xenogeneic differences between human and murine sequences might be exploited to develop more immunogenic tumor vaccines.
Literatur
1.
Zurück zum Zitat Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57:1419–1424PubMed Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57:1419–1424PubMed
2.
Zurück zum Zitat Heimberger AB, Crotty LE, Archer GE et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247–4254PubMed Heimberger AB, Crotty LE, Archer GE et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247–4254PubMed
3.
Zurück zum Zitat Ciesielski MJ, Kazim L, Barth RF, Fenstermaker RA (2005) Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 54:107–119CrossRefPubMed Ciesielski MJ, Kazim L, Barth RF, Fenstermaker RA (2005) Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 54:107–119CrossRefPubMed
4.
Zurück zum Zitat Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487–8491PubMed Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487–8491PubMed
5.
Zurück zum Zitat Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMed Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43–49PubMed
6.
Zurück zum Zitat Kajiwara Y, Yamasaki F, Hama S et al (2003) Expression of survivin in astrocytic tumors. Cancer 97:1077–1083CrossRefPubMed Kajiwara Y, Yamasaki F, Hama S et al (2003) Expression of survivin in astrocytic tumors. Cancer 97:1077–1083CrossRefPubMed
7.
Zurück zum Zitat Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin an inhibitor of apoptosis protein in tumors of the nervous system. Acta Neuropathol (Berl) 104:105–109CrossRef Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin an inhibitor of apoptosis protein in tumors of the nervous system. Acta Neuropathol (Berl) 104:105–109CrossRef
8.
Zurück zum Zitat Chakravarti A, Noll E, Black P et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068CrossRefPubMed Chakravarti A, Noll E, Black P et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068CrossRefPubMed
9.
Zurück zum Zitat Islam A, Kageyama H, Takada N et al (2000) A high expression of survivin mapped to 17q25 is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623CrossRefPubMed Islam A, Kageyama H, Takada N et al (2000) A high expression of survivin mapped to 17q25 is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19:617–623CrossRefPubMed
10.
Zurück zum Zitat Satoh K, Kaneko K, Hirota M et al (2001) T expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271–278CrossRefPubMed Satoh K, Kaneko K, Hirota M et al (2001) T expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271–278CrossRefPubMed
11.
Zurück zum Zitat Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54CrossRefPubMed Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54CrossRefPubMed
12.
Zurück zum Zitat Overwijk WW, Tsung A, Irvine KR et al (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 188:277–286CrossRefPubMed Overwijk WW, Tsung A, Irvine KR et al (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 188:277–286CrossRefPubMed
13.
Zurück zum Zitat Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452CrossRef Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452CrossRef
14.
Zurück zum Zitat Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473CrossRef Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473CrossRef
15.
Zurück zum Zitat Patel AK, Boyd PN (1995) An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J Immunol Methods 184(1):29–38CrossRefPubMed Patel AK, Boyd PN (1995) An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J Immunol Methods 184(1):29–38CrossRefPubMed
16.
Zurück zum Zitat Liau LM, Black KL, Martin NA et al (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 9:8CrossRef Liau LM, Black KL, Martin NA et al (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 9:8CrossRef
17.
Zurück zum Zitat Yu JS, Wheeler CJ, Zeltzer PM et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847PubMed Yu JS, Wheeler CJ, Zeltzer PM et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847PubMed
18.
Zurück zum Zitat Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4999CrossRefPubMed Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4999CrossRefPubMed
19.
Zurück zum Zitat Kikuchi T, Akasaki Y, Irie M et al (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344CrossRefPubMed Kikuchi T, Akasaki Y, Irie M et al (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344CrossRefPubMed
20.
Zurück zum Zitat Zhao J, Tenev T, Martins LM et al (2000) The ubiquitin-proteosome pathway regulates survivin degradation in a cell-cycle dependent manner. J Cell Sci 113:4363–4371PubMed Zhao J, Tenev T, Martins LM et al (2000) The ubiquitin-proteosome pathway regulates survivin degradation in a cell-cycle dependent manner. J Cell Sci 113:4363–4371PubMed
21.
Zurück zum Zitat Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584CrossRefPubMed Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584CrossRefPubMed
22.
Zurück zum Zitat Fortugno P, Wall NR, Giodini A et al (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115:575–585PubMed Fortugno P, Wall NR, Giodini A et al (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115:575–585PubMed
23.
Zurück zum Zitat Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95) Bax caspases and anticancer drugs. Cancer Res 58:5215–5220 Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95) Bax caspases and anticancer drugs. Cancer Res 58:5215–5220
24.
Zurück zum Zitat Conway EM, Pollefeyt S, Cornelissen J et al (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435–1442PubMed Conway EM, Pollefeyt S, Cornelissen J et al (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435–1442PubMed
25.
Zurück zum Zitat Shin S, Sung BJ, Cho Y et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123CrossRefPubMed Shin S, Sung BJ, Cho Y et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123CrossRefPubMed
26.
Zurück zum Zitat Fududa S, Mantel CR, Pelus LM (2004) Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1 dependent and independent pathways. Blood 103:120–127CrossRefPubMed Fududa S, Mantel CR, Pelus LM (2004) Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1 dependent and independent pathways. Blood 103:120–127CrossRefPubMed
27.
Zurück zum Zitat Suzuki A, Hayashida M, Ito T et al (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 19:3225–3334CrossRefPubMed Suzuki A, Hayashida M, Ito T et al (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 19:3225–3334CrossRefPubMed
28.
Zurück zum Zitat Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635–640CrossRefPubMed Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635–640CrossRefPubMed
29.
Zurück zum Zitat Mesri M, Wall NR, Li J et al (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108:981–990CrossRefPubMed Mesri M, Wall NR, Li J et al (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108:981–990CrossRefPubMed
30.
Zurück zum Zitat Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553–561PubMed Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553–561PubMed
31.
Zurück zum Zitat Zeis M, Siegel S, Wagner A et al (2003) A generation of cytotoxic responses in mice and human individually against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391–5397PubMed Zeis M, Siegel S, Wagner A et al (2003) A generation of cytotoxic responses in mice and human individually against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391–5397PubMed
32.
Zurück zum Zitat Andersen MH, Pedersen LO, Becker JC, Straten P (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61:869–872PubMed Andersen MH, Pedersen LO, Becker JC, Straten P (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61:869–872PubMed
33.
Zurück zum Zitat Schmitz M, Diestelkoetter P, Weigle B et al (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845–4849PubMed Schmitz M, Diestelkoetter P, Weigle B et al (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845–4849PubMed
34.
Zurück zum Zitat Yamanaka R, Yajima N, Abe T et al (2003) Dendritic cell-based glioma immunotherapy. Int J Oncol 23:5–15PubMed Yamanaka R, Yajima N, Abe T et al (2003) Dendritic cell-based glioma immunotherapy. Int J Oncol 23:5–15PubMed
35.
Zurück zum Zitat Yang L, Ng KY, Lillehei KO (2003) Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10:138–147PubMed Yang L, Ng KY, Lillehei KO (2003) Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10:138–147PubMed
36.
Zurück zum Zitat Ehtesham M, Black KL, Yu JS (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11:192–207PubMed Ehtesham M, Black KL, Yu JS (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11:192–207PubMed
37.
Zurück zum Zitat Dunn GP, Bruce AT, Ikeda H (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998CrossRefPubMed Dunn GP, Bruce AT, Ikeda H (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998CrossRefPubMed
38.
Zurück zum Zitat Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452CrossRef Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:2445–2452CrossRef
39.
Zurück zum Zitat Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473CrossRef Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 4:459–473CrossRef
40.
Zurück zum Zitat Ni HT, Spellman SR, Jean WC et al (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9CrossRefPubMed Ni HT, Spellman SR, Jean WC et al (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9CrossRefPubMed
41.
Zurück zum Zitat Aoki H, Mizuno M, Natsume A et al (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463–468CrossRefPubMed Aoki H, Mizuno M, Natsume A et al (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463–468CrossRefPubMed
42.
Zurück zum Zitat Gordan JD, Vonderheide RH (2002) Universal tumor antigens as targets for immunotherapy. Cytotherapy 4:317–327CrossRefPubMed Gordan JD, Vonderheide RH (2002) Universal tumor antigens as targets for immunotherapy. Cytotherapy 4:317–327CrossRefPubMed
44.
Zurück zum Zitat O’Connor DS, Schechner JS, Adida C et al (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393–398PubMed O’Connor DS, Schechner JS, Adida C et al (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393–398PubMed
45.
Zurück zum Zitat Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547CrossRefPubMed Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547CrossRefPubMed
46.
Zurück zum Zitat Andersen MH, Pedersen LO, Capeller B et al (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964–5968PubMed Andersen MH, Pedersen LO, Capeller B et al (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964–5968PubMed
47.
Zurück zum Zitat Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH (2004) Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3(2):173–179PubMed Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH (2004) Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3(2):173–179PubMed
48.
Zurück zum Zitat Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant gliomas. Cancer Control 11:181–191PubMed Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant gliomas. Cancer Control 11:181–191PubMed
49.
Zurück zum Zitat Hawkins WG, Gold JS, Dyall R (2000) Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273–280CrossRefPubMed Hawkins WG, Gold JS, Dyall R (2000) Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273–280CrossRefPubMed
50.
Zurück zum Zitat Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S (2005) Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 174:7104–7110PubMed Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S (2005) Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 174:7104–7110PubMed
51.
Zurück zum Zitat Kieber-Emmons TB, Monzavi-Karbassi B, Wang P et al (2000) Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J Immunol 165:623PubMed Kieber-Emmons TB, Monzavi-Karbassi B, Wang P et al (2000) Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J Immunol 165:623PubMed
52.
Zurück zum Zitat Cunto-Amesty GP, Luo B, Monzavi-Karbassi A et al (2003) Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol Biol 49:245PubMed Cunto-Amesty GP, Luo B, Monzavi-Karbassi A et al (2003) Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol Biol 49:245PubMed
53.
Zurück zum Zitat Chapman PBD, Wu G, Ragupathi S et al (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717CrossRefPubMed Chapman PBD, Wu G, Ragupathi S et al (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717CrossRefPubMed
Metadaten
Titel
Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas
verfasst von
Michael J. Ciesielski
Lisa Apfel
Tara A. Barone
Carla A. Castro
Tina C. Weiss
Robert A. Fenstermaker
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0138-6

Weitere Artikel der Ausgabe 12/2006

Cancer Immunology, Immunotherapy 12/2006 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.